An announcement from Percheron Therapeutics ( (AU:PER) ) is now available.
Percheron Therapeutics has announced a strategic shift in its R&D pipeline, deciding to discontinue the ATL1103 program and halt significant investment in the ATL1102 program, which will be retained for potential partnerships. The company is actively seeking new assets to rebuild its pipeline, with several in-licensing opportunities under negotiation. Cost containment measures, including staff reductions and deferred salaries, have been implemented to extend the company’s financial runway. The recent analysis of the ATL1102 phase IIb study in DMD confirmed insufficient efficacy, leading to the study’s termination and a focus on winding down related activities while ensuring regulatory compliance.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for rare diseases. The company is listed on the Australian Securities Exchange (ASX) and the US OTCQB market, with a market focus on advancing treatments for conditions such as Duchenne muscular dystrophy (DMD) and autoimmune epilepsy.
Technical Sentiment Signal: Sell
Current Market Cap: $6.99M
For an in-depth examination of PER stock, go to TipRanks’ Stock Analysis page.